Drug Profile
Ximelagatran
Alternative Names: Exanta™; H 376; H 376/95; H 37695Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator AstraZeneca
- Class Antithrombotics
- Mechanism of Action Thrombin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Market Withdrawal Deep vein thrombosis; Thromboembolism
- Discontinued Postmyocardial infarction; Stroke